UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of: April, 2004
Commission File Number: 000-50393
NEUROCHEM INC.
7220 Frederick-Banting, Suite 100
Saint-Laurent, Quebec
H4S 2A1
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F. Form 20-F [ ] Form 40-F [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes [ ] No [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes [ ] No [X]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES:
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NEUROCHEM INC.
April 28, 2004
By: /s/ David Skinner
------------------------------------
David Skinner
Director, Legal Affairs,
General Counsel and Corporate Secretary
NEUROCHEM INC.
7220 Frederick-Banting, Suite 100
[LOGO (NEUROCHEM)] Saint-Laurent, Qc H4S 2A1 Canada
________________________________________________________________________________
NEUROCHEM TO PRESENT AT
CIBC WORLD MARKETS ANNUAL BIOTECHNOLOGY
AND SPECIALTY PHARMACEUTICALS CONFERENCE
MONTREAL, CANADA, APRIL 27, 2004 - Neurochem Inc. (NASDAQ: NRMX, TSX: NRM)
announced today that on Wednesday April 28, 2004, Dr. Francesco Bellini,
Chairman and CEO, will present Neurochem's overall strategy and progress to date
at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals
Conference to be held in New York City. The presentation will take place at 2:45
P.M. EDT. The corporate presentation will be available on the Company's website
at http://www.neurochem.com/Investor.htm#Presentation.
An audio webcast of Neurochem's presentation can also be accessed at
http://www.veracast.com/webcasts/cibcwm/biotech04/01212215.cfm. This webcast
will be available for 30 days through to May 28, 2004.
ABOUT NEUROCHEM
Neurochem is focused on the development and commercialization of innovative
therapeutics for neurological disorders. The Company's pipeline of proprietary,
disease-modifying, oral products addresses critical unmet medical needs.
Fibrillex(TM), designated an orphan drug and a Fast Track Product candidate, is
in a Phase II/III clinical trial for AA amyloidosis. Alzhemed(TM) and
Cerebril(TM) have completed a Phase II clinical trial for Alzheimer's Disease
and for the prevention of hemorrhagic stroke caused by cerebral amyloid
angiopathy respectively. For additional information on Neurochem, please visit
our website at: www.neurochem.com.
Certain statements contained in this news release, other than statements of fact
that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties,
known and unknown, many of which are beyond Neurochem's control. Such risks
include but are not limited to: the impact of general economic conditions,
general conditions in the pharmaceutical industry, changes in the regulatory
environment in the jurisdictions in which Neurochem does business, stock market
volatility, fluctuations in costs, and changes to the competitive environment
due to consolidation as well as other risks included in public filings of
Neurochem. Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. The reader
should not place undue reliance on the forward-looking statements included in
this news release. These statements speak only as of the date made and Neurochem
is under no obligation and disavows any intention to update or revise such
statements as a result of any event, circumstances or otherwise.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Lise Hebert, Ph.D.
Vice President, Corporate Communications
lhebert@neurochem.com
- ---------------------
Tel: (514) 337-4646
Fax: (514) 337-5339